小牛脾提取物注射液对晚期恶性肿瘤患者的疗效、免疫功能的影响
|
摘要
目的探讨小牛脾提取物注射液对晚期恶性肿瘤患者的疗效、免疫功能的影响。方法选择晚期恶性肿瘤患者160例,常规组给予基础治疗,实验组加用小牛脾提取物注射液,对比两组疗效。结果实验组与常规组的缓解率分别为55.00%与43.75%,P <0.05;治疗后实验组的T细胞亚群检测值明显优于常规组,P <0.05;实验组不良反应发生率明显低于常规组,P <0.05。结论对晚期恶性肿瘤患者给予小牛脾提取物注射液便于改善其免疫功能,减少不良反应。
Objective To explore effects of calf spleen extractive injection on curative effect and immune function of patients with advanced malignant tumor. Methods 160 patients with advanced malignant tumors were selected. The conventional group was given basic treatment while the experimental group was given basic treatment and calf spleen extractive injection. Curative effects of two groups were compared. Results Remission rates of the experimental group and the conventional group were 55.00% and 43.75% respectively, P < 0.05. After treatment, the T-cell subgroup detection value of the experimental group was significantly better than that of the conventional group, P < 0.05. The incidence of adverse reactions in the experimental group was significantly lower than that in the conventional group, P< 0.05. Conclusion Administration of calf spleen extractive injection to patients with advanced malignant tumors can improve their immune function and reduce adverse reactions.
Objective To explore effects of calf spleen extractive injection on curative effect and immune function of patients with advanced malignant tumor. Methods 160 patients with advanced malignant tumors were selected. The conventional group was given basic treatment while the experimental group was given basic treatment and calf spleen extractive injection. Curative effects of two groups were compared. Results Remission rates of the experimental group and the conventional group were 55.00% and 43.75% respectively, P < 0.05. After treatment, the T-cell subgroup detection value of the experimental group was significantly better than that of the conventional group, P < 0.05. The incidence of adverse reactions in the experimental group was significantly lower than that in the conventional group, P< 0.05. Conclusion Administration of calf spleen extractive injection to patients with advanced malignant tumors can improve their immune function and reduce adverse reactions.
引文
[1]倪渐凤.小牛脾提取物注射液对晚期恶性肿瘤患者免疫功能的影响[J].临床医药文献电子杂志,2016,3(11):2187-2188.
[2]彭恩兰.小牛脾提取物注射液治疗肿瘤相关性红细胞减少的临床观察[J].实用癌症杂志,2013,28(6):623-624.
[3]刘钊,张西园,马骏卿,等.小牛脾提取物注射液联合多西他赛加卡培他滨方案治疗晚期乳腺癌临床观察[J].肿瘤防治研究,2014,41(10):1116-1119.
[4]白羽霞,韩晟,李文胜,等.小牛脾提取物注射液辅助化疗治疗肿瘤疗效与安全性的Meta分析[J].中国药房,2015,26(36):5119-5122.
[5]杨军,仲华,杨庆辉,等.小牛脾提取物注射液在局部晚期头颈肿瘤同步放化疗中对骨髓的影响[J].中国民康医学,2017,29(16):100-101.
[6]黄慧,朱伟旺,李伟坚,等.小牛脾提取物注射液联合应用甲泼尼龙对ARDS患者炎性因子及治疗效果的影响[J].国际呼吸杂志,2017,37(3):198-201.
[7]白羽霞,韩晟,李文胜,等.小牛脾提取物(斯普林)注射液循证药物经济学研究[C].//2014年中国药学大会暨第十四届中国药师周论文集,2014:1-15.
[8]黄凌莉,魏青,王蕾,等.小牛脾提取物注射液致严重不良反应1例[J].临床合理用药杂志,2015,8(34):84,157.
[9]顾佳颖,胡春梅,石光,等.CD4+、CD8+细胞水平变化与恶性肿瘤疗效的关系[J].中国老年学杂志,2015,35(22):6454-6455.
[10]王芳,周玉峰,沈燕,等.恶性肿瘤患儿化疗后感染风险评估表的研制[J].中国实用护理杂志,2014,30(22):28-32.
[11]夏荣涛.恶性肿瘤合并上腔静脉综合征患者放化疗的疗效分析[J].中国急救医学,2016,36(z1):181-182.
[12]柯蔚,张晓琛,俞素芬,等.晚期胆系恶性肿瘤化疗方案的回顾性研究[J].中国肿瘤临床,2017,44(9):429-433.
[13]金知萍,许青,吕迁洲,等.我院135例肺恶性肿瘤患者化疗致便秘的相关因素及防治方案的调查分析[J].中国药房,2017,28(30):4190-4193.
[14]黄翠红,陈秀梅,黄翠娟,等.植入式静脉输液港与经外周中心静脉置管在化疗患者中的应用效果比较[J].广东医学,2016,37(3):472-473.
[15]杨霖,王笑民,念家云,等.恶性肿瘤患者化疗相关性口腔黏膜炎的中西医药物治疗进展[J].世界科学技术-中医药现代化,2016,18(5):883-888.
[16]兰四友,张德芬,邓述恺,等.小牛脾提取物联合化疗治疗小细胞肺癌的临床疗效[J].中国老年学杂志,2017,37(2):401-403.
[17]刘晓玲.小牛脾提取物注射液治疗晚期非小细胞肺癌49例[J].中国药业,2015,24(23):159-161.
[18]王春霞,武娟娟.小牛脾提取物注射液联合化疗治疗非小细胞肺癌32例临床观察[J].山西医药杂志,2013,42(3):174-175.
[19]钱朋飞,邹燕鹏,黎冠宏,等.小牛脾提取物对晚期乳腺癌化疗性贫血及免疫功能的影响[J].中国临床医生杂志,2017,45(2):66-69,70.
[20]许伟,卢小冬,沙德胜,等.小牛脾提取物注射液配合化疗对晚期乳腺癌患者细胞亚群及VEGF、FGF的影响[J].标记免疫分析与临床,2017,24(10):1149-1153.
[2]彭恩兰.小牛脾提取物注射液治疗肿瘤相关性红细胞减少的临床观察[J].实用癌症杂志,2013,28(6):623-624.
[3]刘钊,张西园,马骏卿,等.小牛脾提取物注射液联合多西他赛加卡培他滨方案治疗晚期乳腺癌临床观察[J].肿瘤防治研究,2014,41(10):1116-1119.
[4]白羽霞,韩晟,李文胜,等.小牛脾提取物注射液辅助化疗治疗肿瘤疗效与安全性的Meta分析[J].中国药房,2015,26(36):5119-5122.
[5]杨军,仲华,杨庆辉,等.小牛脾提取物注射液在局部晚期头颈肿瘤同步放化疗中对骨髓的影响[J].中国民康医学,2017,29(16):100-101.
[6]黄慧,朱伟旺,李伟坚,等.小牛脾提取物注射液联合应用甲泼尼龙对ARDS患者炎性因子及治疗效果的影响[J].国际呼吸杂志,2017,37(3):198-201.
[7]白羽霞,韩晟,李文胜,等.小牛脾提取物(斯普林)注射液循证药物经济学研究[C].//2014年中国药学大会暨第十四届中国药师周论文集,2014:1-15.
[8]黄凌莉,魏青,王蕾,等.小牛脾提取物注射液致严重不良反应1例[J].临床合理用药杂志,2015,8(34):84,157.
[9]顾佳颖,胡春梅,石光,等.CD4+、CD8+细胞水平变化与恶性肿瘤疗效的关系[J].中国老年学杂志,2015,35(22):6454-6455.
[10]王芳,周玉峰,沈燕,等.恶性肿瘤患儿化疗后感染风险评估表的研制[J].中国实用护理杂志,2014,30(22):28-32.
[11]夏荣涛.恶性肿瘤合并上腔静脉综合征患者放化疗的疗效分析[J].中国急救医学,2016,36(z1):181-182.
[12]柯蔚,张晓琛,俞素芬,等.晚期胆系恶性肿瘤化疗方案的回顾性研究[J].中国肿瘤临床,2017,44(9):429-433.
[13]金知萍,许青,吕迁洲,等.我院135例肺恶性肿瘤患者化疗致便秘的相关因素及防治方案的调查分析[J].中国药房,2017,28(30):4190-4193.
[14]黄翠红,陈秀梅,黄翠娟,等.植入式静脉输液港与经外周中心静脉置管在化疗患者中的应用效果比较[J].广东医学,2016,37(3):472-473.
[15]杨霖,王笑民,念家云,等.恶性肿瘤患者化疗相关性口腔黏膜炎的中西医药物治疗进展[J].世界科学技术-中医药现代化,2016,18(5):883-888.
[16]兰四友,张德芬,邓述恺,等.小牛脾提取物联合化疗治疗小细胞肺癌的临床疗效[J].中国老年学杂志,2017,37(2):401-403.
[17]刘晓玲.小牛脾提取物注射液治疗晚期非小细胞肺癌49例[J].中国药业,2015,24(23):159-161.
[18]王春霞,武娟娟.小牛脾提取物注射液联合化疗治疗非小细胞肺癌32例临床观察[J].山西医药杂志,2013,42(3):174-175.
[19]钱朋飞,邹燕鹏,黎冠宏,等.小牛脾提取物对晚期乳腺癌化疗性贫血及免疫功能的影响[J].中国临床医生杂志,2017,45(2):66-69,70.
[20]许伟,卢小冬,沙德胜,等.小牛脾提取物注射液配合化疗对晚期乳腺癌患者细胞亚群及VEGF、FGF的影响[J].标记免疫分析与临床,2017,24(10):1149-1153.